Fundraising FoxOnconano
Dallas, US · Founded 2014 · 1 known investors
Find your way into Onconano
Sign up to see every warm intro you have to Onconano
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Onconano team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
OncoNano Medicine develops a proprietary nanotechnology platform for cancer therapeutics that targets the acidic tumor microenvironment to improve drug delivery to tumors. The company serves oncology patients and builds a pipeline of therapies designed for more precise cancer treatment.
Founders & leadership
MP
Melissa PaoloniExecutiveMelissa Paoloni is Executive Officer at OncoNano Medicine, where she oversees corporate operations, business development, strategic partnerships, and portfolio management. She brings experience in pharmaceutical licensing, clinical development, and investor relations.
MH
Matthew HeadExecutiveHe brings experience in operational finance, commercial banking, and corporate communications across both startup and large corporate environments.
KK
Kartik KrishnanExecutiveKartik Krishnan is an executive with experience as an academic physician-scientist and clinical leadership roles in biotech, including prior positions in pharmacovigilance and as Chief Executive Officer. He brings expertise in drug development from preclinical through Phase 3 clinical trials, with particular focus on oncology including solid tumors and hematologic malignancies.
GG
Gina Guillem JonesMMS, PhD
BQ
Benjamin QuiCFA, CMA
JG
Joydeep GoswamiNamed on SEC filing
PD
Paritosh DhawaleNamed on SEC filing
AG
Alvaro GuillemNamed on SEC filing
RS
Ravi SrinivasanNamed on SEC filing
BS
Brent SorrellsNamed on SEC filing
Board
JD
John DyettBoard director
YQ
Yumin QuiBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$115M disclosed across 3 rounds · 2018–2025
▶$10.1MraisedOct 2026 · 14 investors · BiotechnologyRule 506(b)
▶$10.1MraisedOct 2026 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brent SorrellsExecutive Officer
- Brett GiroirExecutive Officer, Director
- John DyettDirector
- Gina JonesDirector
- Yumin QuiDirector
- Offering amount
- $15M
- Amount sold
- $10.1M
- Sales commissions
- $402.1K
- Placement agents
- Salem Partners LLC
- First sale
- Sep 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.7MraisedJun 2025 · 25 investors · BiotechnologyRule 506(b)
▶$12.7MraisedJun 2025 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John DyettDirector
- Gina JonesDirector
- Melissa PaoloniExecutive Officer
- Matthew HeadExecutive Officer
- Brett GiroirDirector
- Yumin QuiDirector
- Kartik KrishnanExecutive Officer, Director
- Offering amount
- $12.7M
- Amount sold
- $12.7M
- Sales commissions
- $634.9K
- Placement agents
- Salem Partners LLC
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$68.4MraisedNov 2021 · 27 investors · BiotechnologyRule 506(b)
▶$68.4MraisedNov 2021 · 27 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Martin DriscollExecutive Officer, Director
- Alvaro GuillemDirector
- Yumin QiuDirector
- Matthew HeadExecutive Officer
- John DyettDirector
- Offering amount
- $68.4M
- Amount sold
- $68.4M
- Finders' fees
- $2.5M
- Placement agents
- Salem Partners LLC
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$33.9MraisedApr 2019 · 39 investors · BiotechnologyRule 506(b)
▶$33.9MraisedApr 2019 · 39 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joydeep GoswamiDirector
- John DyettDirector
- Matthew HeadExecutive Officer
- Paritosh DhawaleDirector
- Alvaro GuillemDirector
- Ravi SrinivasanExecutive Officer, Director
- Offering amount
- $35.4M
- Amount sold
- $33.9M
- Finders' fees
- $600K
- Placement agents
- Salem Partners LLC
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Onconano do?
- OncoNano Medicine develops a proprietary nanotechnology platform for cancer therapeutics that targets the acidic tumor microenvironment to improve drug delivery to tumors. The company serves oncology patients and builds a pipeline of therapies designed for more precise cancer treatment.
- Who are Onconano's investors?
- Onconano's investors include Green Park & Golf Ventures.
- How much funding has Onconano raised?
- Onconano has disclosed $115M raised across 3 rounds.
- Where is Onconano headquartered?
- Onconano is headquartered in Dallas, US.